SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001144204-15-046001
Filing Date
2015-08-04
Accepted
2015-08-04 12:15:40
Documents
1
Group Members
FORESITE CAPITAL FUND I, L.P.FORESITE CAPITAL FUND II, L.P.FORESITE CAPITAL MANAGEMENT I, LLCFORESITE CAPITAL MANAGEMENT II, LLCFORESITE CAPITAL MANAGEMENT III, LLCJAMES TANANBAUM

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13G v417074_sc13g.htm SC 13G 121937
  Complete submission text file 0001144204-15-046001.txt   123747
Mailing Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037
Business Address 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 (858) 875-8600
Orexigen Therapeutics, Inc. (Subject) CIK: 0001382911 (see all company filings)

IRS No.: 651178822 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-83422 | Film No.: 151024650
SIC: 2834 Pharmaceutical Preparations

Mailing Address 101 CALIFORNIA STREET, SUITE 4100 SAN FRANCISCO CA 94111
Business Address 101 CALIFORNIA STREET, SUITE 4100 SAN FRANCISCO CA 94111 415-877-4887
Foresite Capital Fund III, L.P. (Filed by) CIK: 0001645158 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G